Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy - AMPLIFY

Description:

Apixaban is a novel oral anti-Xa antagonist, with demonstrated safety and efficacy as compared with agents such as warfarin in patients with atrial fibrillation and enoxaparin in patients undergoing orthopedic surgery. Recently, in the AMPLIFY-EXT trial, apixaban demonstrated superiority over placebo for reducing recurrent thromboembolic events in patients with established venous thromboembolism (VTE). The current trial sought to study the safety and efficacy of apixaban as compared with convent...